ROYAL BANK OF CANADA - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$1,273,000
-51.4%
35,749
-37.0%
0.00%
-100.0%
Q2 2023$2,618,000
+15.0%
56,735
-0.1%
0.00%0.0%
Q1 2023$2,277,000
+1055.8%
56,778
+1236.0%
0.00%
Q4 2022$197,000
+27.1%
4,250
+13.0%
0.00%
Q3 2022$155,000
-62.2%
3,760
-45.1%
0.00%
Q2 2022$410,000
-22.1%
6,852
-5.5%
0.00%
Q1 2022$526,000
-28.3%
7,251
-16.9%
0.00%
Q4 2021$734,000
+2.1%
8,727
+9.3%
0.00%
Q3 2021$719,000
-76.4%
7,988
-75.0%
0.00%
-100.0%
Q2 2021$3,052,000
+319.8%
32,006
+401.7%
0.00%
Q1 2021$727,000
+6.0%
6,379
+28.6%
0.00%
Q4 2020$686,000
+253.6%
4,961
+109.8%
0.00%
Q3 2020$194,000
+104.2%
2,365
+95.6%
0.00%
Q2 2020$95,000
+1087.5%
1,209
+598.8%
0.00%
Q1 2020$8,000
-92.5%
173
-93.2%
0.00%
Q4 2019$107,000
+64.6%
2,531
+64.5%
0.00%
Q3 2019$65,000
+441.7%
1,539
+650.7%
0.00%
Q2 2019$12,000
-85.9%
205
-83.2%
0.00%
Q1 2019$85,000
+102.4%
1,223
+28.1%
0.00%
Q4 2018$42,000
-75.6%
955
-57.6%
0.00%
Q3 2018$172,000
+11.0%
2,255
+11.4%
0.00%
Q2 2018$155,000
+868.8%
2,025
+526.9%
0.00%
Q1 2018$16,000
-99.9%
323
-99.9%
0.00%
-100.0%
Q4 2017$12,608,000
+2.9%
271,845
+18.1%
0.01%0.0%
Q3 2017$12,253,000
-12.0%
230,087
+2.6%
0.01%
-14.3%
Q2 2017$13,929,000
+846.9%
224,261
+933.2%
0.01%
+600.0%
Q1 2017$1,471,000
-86.5%
21,705
-86.0%
0.00%
-83.3%
Q4 2016$10,885,000
-6.7%
154,804
-5.9%
0.01%0.0%
Q3 2016$11,672,000
+78.9%
164,538
+23.3%
0.01%
+50.0%
Q2 2016$6,526,000
-10.7%
133,424
+15.5%
0.00%
-20.0%
Q1 2016$7,311,000
+182675.0%
115,483
+360784.4%
0.01%
Q4 2015$4,000
-97.7%
32
-98.2%
0.00%
Q3 2015$173,000
-59.8%
1,798
-57.2%
0.00%
Q2 2015$430,000
-38.7%
4,200
-62.8%
0.00%
Q1 2015$702,00011,3000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2018
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders